Bosentan: A Review of its Use in the Management of Mildly Symptomatic Pulmonary Arterial Hypertension

Authors: Dhillon, Sohita; Keating, Gillian M.

Source: American Journal of Cardiovascular Drugs, Volume 9, Number 5, 1 October 2009 , pp. 331-350(20)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

Abstract Bosentan (Tracleer®) is an orally administered dual endothelin-1 (ET-1) receptor antagonist approved for use in patients with WHO class II (mildly symptomatic) pulmonary arterial hypertension (PAH).

Oral bosentan therapy was beneficial and generally well tolerated in patients with mildly symptomatic PAH. In a well designed, placebo-controlled trial in adolescents and adults with mildly symptomatic PAH, pulmonary vascular resistance was significantly reduced with bosentan relative to placebo, but the 6-minute walk distance did not increase significantly. Similarly, pediatric patients (most of whom had mildly symptomatic PAH) in a small uncontrolled trial experienced some improvement in hemodynamic variables with bosentan, but did not experience a significant increase in exercise capacity. Adverse events associated with bosentan were consistent with those seen in other indications, with major concerns being the potential for teratogenicity and hepatotoxicity, for which regular liver function monitoring is recommended. Overall, considering the progressive nature of PAH, bosentan extends the treatment options available to patients with mildly symptomatic PAH.

Document Type: Research article

Affiliations: 1: Adis, a Wolters Kluwer Business, Auckland, New Zealand

Publication date: 2009-10-01